A detailed history of Emerald Advisers, LLC transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Emerald Advisers, LLC holds 401,611 shares of ITCI stock, worth $27.7 Million. This represents 1.18% of its overall portfolio holdings.

Number of Shares
401,611
Previous 343,820 16.81%
Holding current value
$27.7 Million
Previous $24.6 Million 12.86%
% of portfolio
1.18%
Previous 1.1%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 08, 2024

BUY
$64.37 - $75.65 $3.72 Million - $4.37 Million
57,791 Added 16.81%
401,611 $27.8 Million
Q4 2023

Feb 05, 2024

SELL
$46.37 - $73.65 $1.76 Million - $2.79 Million
-37,920 Reduced 9.93%
343,820 $24.6 Million
Q3 2023

Oct 26, 2023

BUY
$52.09 - $64.1 $2.43 Million - $2.99 Million
46,574 Added 13.9%
381,740 $19.9 Million
Q2 2023

Jul 25, 2023

BUY
$54.67 - $66.44 $18.3 Million - $22.3 Million
335,166 New
335,166 $21.2 Million

Others Institutions Holding ITCI

About Intra-Cellular Therapies, Inc.


  • Ticker ITCI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 94,401,696
  • Market Cap $6.52B
  • Description
  • Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...
More about ITCI
Track This Portfolio

Track Emerald Advisers, LLC Portfolio

Follow Emerald Advisers, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Emerald Advisers, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Emerald Advisers, LLC with notifications on news.